Pacgen Starts Trial for PAC-113

Canadian drugmaker Pacgen Biopharmaceuticals has begun a Phase IIb dose-ranging trial for an optimized formulation of PAC-113, a treatment for oral candidiasis infection.

The randomized, examiner-blind, parallel-design trial will compare three doses of PAC-113 with Nystatin, a mouth rinse treatment for oral candidiasis. The study will enroll approximately 200 seropositive HIV patients with oral candidiasis in the U.S. and South Africa.

Pacgen said it anticipates completing the trial in the second quarter of 2008.